• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NASDAQ halts trading in HeartWare shares ahead of FDA panel vote

NASDAQ halts trading in HeartWare shares ahead of FDA panel vote

April 25, 2012 By MassDevice staff

MassDevice.com news

Early indications that the FDA is likely to approve an implantable heart pump made by HeartWare International (NSDQ:HTWR) pushed its shares up nearly 7% this week, prompting the NASDAQ stock exchange to halt trading of the shares today as an agency panel considers the company’s pre-market approval application.

HTWR shares gained 6.8% Monday after documents released ahead of the meeting indicated that the Center for Devices & Radiological Health’s circulatory devices panel is likely to recommend approval of the HeartWare left ventricular assist device.

HeartWare wants the federal watchdog agency to approve the pump for use in patients with end-stage heart failure who are waiting for a heart transplant. If the FDA OKs the device, it will plunge HeartWare further into competition with rival Thoratec (NSDQ:THOR), which already has bridge-to-transplant approval for its HeartMate II LVAD.

HeartWare shares opened at $68.80 Monday morning on Wall Street, spiking to $72.28 before closing at $71.71 on heavy volume – nearly a million HTWR shares changed hands that day, as investors reacted to analysts’ predictions of success before the circulatory devices panel.

"While there are a number of ‘panel risks’ that will come into focus at HTWR’s 4/25 FDA meeting (which we believe pressured shares over the last 2 months), we believe the most probable outcome is that HTWR’s HVAD device receives a recommendation for approval," Barclays analyst Matthew Taylor wrote in a note to investors after upgrading his rating to "overweight." "On that basis, we think that the stock will work in the near term and are upgrading shares in anticipation of a favorable panel vote."

HTWR shares moved even higher yesterday, peaking at $72.41 before logging a $69.27 close.

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Structural Heart, Wall Street Beat Tagged With: HeartWare International Inc.

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy